Christopher Melani

13PUBLICATIONS
22CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Mar 04, 2026
A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.

Max J Gordon, Milos D Miljkovic, Paige Milhon

|Dec 18, 2025
An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors.

Ana Corrionero, Xiaohu Zhang, Patricia Alfonso

|Jun 16, 2025
The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas.

Rahul Lakhotia, Christopher Melani, Stefania Pittaluga

|Feb 03, 2025
Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas.

Rahul Lakhotia, Christopher Melani, Kieron Dunleavy

|Nov 25, 2024
Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity.

Michele Ceribelli, Frances Anne Tosto, Xiaohu Zhang

|Jun 20, 2024
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga

Pageof 3

Frequent Collaborators

8 joint publications

Mark Roschewski

7 joint publications

Rahul Lakhotia

4 joint publications

Stefania Pittaluga

4 joint publications

Elaine S Jaffe